The present studies were designed to investigate the biology of GZ17-6.02 in VHL mutant RCC, and to define its interaction with the standard of care RCC therapeutic, the multi-kinase inhibitor axitinib. The gene discussed is VHL; the disease is renal cell carcinoma.